BACKGROUND: Children with high-grade glioma still have a poor prognosis despite the use of multimodal therapy including surgery, radiotherapy, and chemotherapy. New therapeutic strategies and methods evaluating such therapies are needed. OBSERVATION: Here we describe a child with anaplastic oligodendroglioma of the spinal cord who was unable to tolerate standard chemoradiotherapy and who had still-vital residual tumour during therapy. A good response was obtained with low-dose metronomic treatment containing vinblastine. The treatment was guided according to gradual response assessed using various positron-emission tomography tracers. CONCLUSIONS: Metronomic treatment guided by positron-emission tomography could be a reasonable option in some high-risk pediatric tumours.

Department of Nuclear Medicine Masaryk Memorial Cancer Institute Brno Czech Republic ; Regional Center for Applied Molecular Oncology Brno Czech Republic

Department of Pathology University Hospital Brno Brno Czech Republic

Department of Pediatric Neurology University Hospital Brno Brno Czech Republic

Department of Pediatric Oncology University Hospital Brno Brno Czech Republic

Department of Pharmacology Masaryk University School of Medicine Brno Czech Republic ; Regional Center for Applied Molecular Oncology Brno Czech Republic

Regional Center for Applied Molecular Oncology Brno Czech Republic ; Department of Pediatric Oncology University Hospital Brno Brno Czech Republic

Zobrazit více v PubMed

Pizzo PA, Poplack DG. Principles and Practice of Pediatric Oncology. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams and Wilkins; 2011.

Pollack IF. The role of surgery in pediatric gliomas. J Neurooncol. 1999;42:271–88. doi: 10.1023/A:1006107227856. PubMed DOI

Cohen KJ, Pollack IF, Zhou T, et al. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro Oncol. 2011;13:317–23. doi: 10.1093/neuonc/noq191. PubMed DOI PMC

Sterba J, Valik D, Mudry P, et al. Combined biodifferentiating and antiangiogenic oral metronomic therapy is feasible and effective in relapsed solid tumors in children: single-center pilot study. Onkologie. 2006;29:308–13. doi: 10.1159/000093474. PubMed DOI

Zapletalova D, André N, Deak L, et al. Metronomic chemotherapy with the combat regimen in advanced pediatric malignancies: a multicenter experience. Oncology. 2012;82:249–60. doi: 10.1159/000336483. PubMed DOI

Bouffet E, Jakacki R, Goldman S, et al. Phase ii study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol. 2012;30:1358–63. doi: 10.1200/JCO.2011.34.5843. PubMed DOI

Persijn van Meerten EL, Gelderblom H, Bloem JL. recist revised: implications for the radiologist. A review article on the modified recist guideline. Eur Radiol. 2010;20:1456–67. doi: 10.1007/s00330-009-1685-y. PubMed DOI PMC

Gehan EA, Tefft MC. Will there be resistance to the recist (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst. 2000;92:179–81. doi: 10.1093/jnci/92.3.179. PubMed DOI

Pasquier E, Kieran MW, Sterba J, et al. Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology. Transl Oncol. 2011;4:203–11. doi: 10.1593/tlo.11124. PubMed DOI PMC

Brugieres L, Pacquement H, Le Deley MC, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol. 2009;27:5056–61. doi: 10.1200/JCO.2008.20.1764. PubMed DOI

Bonadonna G, Zucali R, Monfardini S, De Lena M, Uslenghi C. Combination chemotherapy of Hodgkin’s disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus mopp. Cancer. 1975;36:252–9. doi: 10.1002/1097-0142(197507)36:1<252::AID-CNCR2820360128>3.0.CO;2-7. PubMed DOI

Lafay–Cousin L, Holm S, Qaddoumi I, et al. Weekly vinblastine in pediatric low-grade glioma patients with carboplatin allergic reaction. Cancer. 2005;103:2636–42. doi: 10.1002/cncr.21091. PubMed DOI

Baranzelli MC, Bouffet E, Quintana E, Portas M, Thyss A, Patte C. Non-seminomatous ovarian germ cell tumours in children. Eur J Cancer. 2000;36:376–83. doi: 10.1016/S0959-8049(99)00317-2. PubMed DOI

Vacca A, Iurlaro M, Ribatti D, et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood. 1999;94:4143–55. PubMed

Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and vegf receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest. 2000;105:R15–24. doi: 10.1172/JCI8829. PubMed DOI PMC

Tanaka H, Matsushima H, Nishibu A, Clausen BE, Takashima A. Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res. 2009;69:6987–94. doi: 10.1158/0008-5472.CAN-09-1106. PubMed DOI PMC

Borgwardt L, Højgaard L, Carstensen H, et al. Increased fluorine-18 2-fluoro-2-deoxy-d-glucose (fdg) uptake in childhood cns tumors is correlated with malignancy grade: a study with fdg positron emission tomography/magnetic resonance imaging coregistration and image fusion. J Clin Oncol. 2005;23:3030–7. doi: 10.1200/JCO.2005.02.074. PubMed DOI

Kumar R, Shandal V, Shamim SA, Halanaik D, Malhotra A. Clinical applications of pet and pet/ct in pediatric malignancies. Expert Rev Anticancer Ther. 2010;10:755–68. doi: 10.1586/era.10.12. PubMed DOI

Chandrasekaran S, Hollander A, Xu X, et al. 18F–Fluorothymidine-pet imaging of glioblastoma multiforme: effects of radiation therapy on radiotracer uptake and molecular biomarker patterns. Scientific World Journal. 2013;2013:796029. doi: 10.1155/2013/796029. PubMed DOI PMC

Kawai N, Shishido H, Yamamoto Y, Nishiyama Y, Tamiya T. Evaluation of brain tumor metabolism with proton magnetic resonance spectroscopy (1H–mrs) and positron emission tomography (pet) with 18F–fluorothymidine (flt) [abstract 1986] J Nucl Med. 2012;53(suppl 1)

Van der Graaf M. In vivo magnetic resonance spectroscopy: basic methodology and clinical applications. Eur Biophys J. 2010;39:527–40. doi: 10.1007/s00249-009-0517-y. PubMed DOI PMC

Torigian DA, Huang SS, Houseni M, Alavi A. Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin. 2007;57:206–24. doi: 10.3322/canjclin.57.4.206. PubMed DOI

Schwarzenberg J, Czernin J, Cloughesy TF, et al. 3′-deoxy-3′-18F-fluorothymidine pet and mri for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med. 2012;53:29–36. doi: 10.2967/jnumed.111.092387. PubMed DOI PMC